ACHIEVE LIFE SCIENCES INC
ACHVNASDAQTrading Snapshot
- Day Range
- $6.90 – $7.23
- 52-Week Range
- $2.62 – $8.64
- Volume (shares)
- 1,374,471
- Avg Volume (shares)
- —
- Shares Outstanding
- 102.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -4.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +54.4%
ACHIEVE LIFE SCIENCES INC
ACHV
StockOtter · stockotter.spaceAbout ACHIEVE LIFE SCIENCES INC
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to cytisin
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global develop
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global developm
Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $7.69, but opened at $8.08. Achieve Life Sciences shares last
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline Brings public company CFO experience across commercial pharma an
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercializatio